Document Detail


Anti-inflammatory therapy for diabetic retinopathy.
MedLine Citation:
PMID:  21554091     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Diabetic retinopathy (DR) is one of the most common complications of diabetes. This devastating disease is a leading cause of blindness in people of working age in industrialized countries and affects the daily lives of millions of people. Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of DR patients keeps growing and therapeutic approaches are limited. Moreover, there are significant limitations and side effects associated with the current therapies. Thus, there is a great need for development of new strategies for prevention and treatment of DR. Studies have shown that DR has prominent features of chronic, subclinical inflammation. This article focuses on the role of inflammation in DR and summarizes the progress of studies of anti-inflammatory strategies for DR.
Authors:
Wenbo Zhang; Hua Liu; Modesto Rojas; Robert W Caldwell; Ruth B Caldwell
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Immunotherapy     Volume:  3     ISSN:  1750-7448     ISO Abbreviation:  Immunotherapy     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101485158     Medline TA:  Immunotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  609-28     Citation Subset:  IM    
Affiliation:
Vascular Biology Center, Georgia Health Sciences University, Augusta, GA, 30912-2500, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  mRNA: delivering an antitumor message?
Next Document:  One century of allergen-specific immunotherapy for respiratory allergy.